磁共振脂肪定量技术在评估化疗患者肝脏脂肪变性程度的应用

Objective To investigate the value of magnetic resonance imaging proton density fat fraction(MRI-PDFF) in the dynamic assessment of chemotherapy-associated fatty liver disease(CALD), and to analyze the impact of different chemotherapy regimens on liver fat content. Methods Thirty patients with solid tumors who received first-line chemotherapy between June 2023 and December 2024 were prospectively enrolled and divided into a taxane group(n=20) and a non-taxane group(n=10) according to the chemotherapy regimen. All patients underwent IDEAL-IQ sequence scanning at baseline, after cycle 2, after cycle 4, and one month after the completion of chemotherapy. Liver PDFF values were measured; their dynamic changes, correlations with liver function indices, and diagnostic performance were analyzed. Results The increase in PDFF was significantly higher in the taxane group than in the nontaxane group(P=0.011), with a continuous rise over the chemotherapy cycles(P<0.001). Cumulative taxane dose was positively correlated with ΔPDFF(P=0.018). Post-chemotherapy PDFF was positively correlated with ALT, AST, and GGT(P<0.05). Conclusion MRI-PDFF can noninvasively and quantitatively monitor dynamic changes in liver fat in chemotherapy patients. Taxane-based agents represent a significant risk factor for the progression of steatosis. PDFF demonstrates high clinical significance in reflecting liver injury and evaluating the degree of hepatic steatosis.